<DOC>
	<DOCNO>NCT00535522</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics TAK-285 patient advanced cancer .</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study TAK-285 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria The subject histologically confirm advanced nonhematologic malignancy . The subject chemotherapyfree interval least 4 week prior first dose study drug . The subject intolerant , candidate , subject 's disease refractory establish therapy know provide clinical benefit disease . A female subject childbearing potential sexually active agrees use adequate contraception Screening throughout duration study , 30 day last dose study drug . Male subject agree use contraception duration study , 30 day last dose study drug . The subject life expectancy great 12 week . The subject Eastern Cooperative Oncology Group performance status 0 2 . The subject ability swallow retain oral medication The subject 's recent test value within 2 week date entry meet following standard : Bone marrow function : Absolute neutrophil count ≥1500/mm3 Hemoglobin ≥9.0g/dL , platelet count ≥100,000/mm3 . Liver function : Total bilirubin ≤1.5 time upper limit standard value institution Aspartate aminotransferase alanine aminotransferase ≤2.5 time upper limit standard value institution . Renal function : Serum creatinine ≤1.5 time upper limit standard value institution . In recommended phase 2 dose Cohort , subject accessible tumor biopsy willing undergo 2 tumor biopsy . In recommended phase 2 dose Cohort , subject least 1 measurable lesion base treatment assessment standard solid tumor . In recommended phase 2 dose Cohort , subject tumor express EGFR and/or overexpresses erbB2 . Exclusion Criteria The subject symptomatic brain metastasis . The subject uncontrollable pleural effusion , ascitic fluid , pericardial effusion . The subject active gastrointestinal bleeding evidence either hematemesis melena . The subject acute gastrointestinal ulcer . The subject treat small molecule inhibitor EGFR HER2 ( except lapatinib ) . The subject history cancer present condition ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 3 year . The subject significant cardiovascular impairment ( history New York Heart Association class III IV ) history myocardial infarction unstable angina within past 6 month prior study drug treatment . The subject severe disease ( cancer ) likely affect prospect survival history make difficult appropriately manage follow progress accordance protocol ( serious organ disorder , mental illness , drug abuse , alcohol dependency , etc. ) . The subject require prohibit treatment ( drug , surgery radiotherapy treatment malignant tumor , drug could interact TAK285 ) except radiotherapy limited area ( &lt; 20 % total bone marrow ) order relieve symptom symptomatic bone metastasis . The subject treat drug , inhibits induces Cytochrome P450 3A4 within 1 week prior start treatment investigational drug . The subject pregnant breast feeding . The subject participate another clinical study/postmarketing clinical study within 4 week prior start treatment TAK285 . The subject currently take exclude medication , include : Concurrent anticancer therapy agent TAK285 . The following prohibited medication substance use least 7 day prior start study throughout completion : Strong CYP3A4 inhibitor Amiodarone Diltiazem Verapamil Human immunodeficiency virus protease inhibitor itraconazole ketoconazole macrolide antibiotic ( exclude azithromycin ) Strong CYP3A4 inducer Carbamazepine Efavirenz Nevirapine Phenytoin Rifabutin Rifampin . St. John 's wort Medications device contain hormone oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>maximal tolerate dose</keyword>
</DOC>